title: Nicardipine sustained release in hypertension.
abstract: 1. A novel formulation of nicardipine (25% standard, 75% sustained release--SR) was evaluated in mild hypertension in a double-blind, randomized, placebo-controlled comparison with standard nicardipine (STD), using clinic measurements (Hawksley) augmented by home recorded blood pressures (Copal UA 251). 2. At 2 h after dosing (peak effect) both STD nicardipine (30 mg three times daily) and SR nicardipine (60 mg twice daily) for 28 days produced a highly significant reduction in sitting and standing blood pressure. The mean sitting blood pressure was reduced by 20/16 mm Hg (STD) and by 25/18 mm Hg (SR) compared with placebo. 3. Predose (8-11 h after last dose of STD, 12-15 h after last dose of SR) the reductions in sitting blood pressure relative to placebo were 11/6 mm Hg (STD) and 14/7 mm Hg (SR). 4. Home recordings confirmed the hypotensive effect of both formulations. Both exhibited a distinct 'peak dose' effect between 1-3 h after dosing. The effect of the SR formulation was sustained throughout the 12 h dosing interval. 5. Of the 60 patients entering the study, one died of unexplained staphylococcal septicaema, two were withdrawn for non drug-related reasons and 14 (32%) were withdrawn because of adverse effects on active therapy (headaches, facial flushing, leg oedema, chest pain, dizziness). 6. In the 43 patients who completed the study adverse symptoms were reported more frequently while they were on the two active formulations of nicardipine compared with placebo. Most of these reactions were again of vasodilator origin.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine and Therapeutics, University of Aberdeen, Foresterhill.
authors.forename: J
authors.initials: J
authors.lastname: Webster
authors.forename: J C
authors.initials: JC
authors.lastname: Petrie
authors.forename: T A
authors.initials: TA
authors.lastname: Jeffers
authors.forename: P
authors.initials: P
authors.lastname: Roy-Chaudhury
authors.forename: W
authors.initials: W
authors.lastname: Crichton
authors.forename: K
authors.initials: K
authors.lastname: Witte
authors.forename: M
authors.initials: M
authors.lastname: Jamieson
authors.forename: F C
authors.initials: FC
authors.lastname: MacDonald
authors.forename: M
authors.initials: M
authors.lastname: Beard
authors.forename: R J
authors.initials: RJ
authors.lastname: Dow
mesh_terms: D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009529:Nicardipine / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D003692:Delayed-Action Preparations; D009529:Nicardipine